Multiple modes of action of the CD38 x ICAM-1 bispecific antibody.

被引：0
|
作者：
Chen, Xiaocheng [1 ]
Wong, Oi Kwan [1 ]
Post, Leonard [1 ]
机构：
[1] Virtuoso Therapeut, San Mateo, CA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5385
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma
    Chen, Xiaocheng
    Wong, Oi Kwan
    Reiman, Lauren
    Sherbenou, Daniel W.
    Post, Leonard
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (02) : 127 - 138
  • [2] CD38 x ICAM1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma
    Chen, Xiaocheng
    Wong, Oi Kwan
    Post, Leonard
    BLOOD, 2021, 138
  • [3] CD47 x ICAM-1 bispecific antibody represents a novel approach for treating ICAM-1 overexpressing tumors
    Wang, Xinhua
    Wong, Oi Kwan
    Post, Leonard
    Chen, Xiaocheng
    CANCER RESEARCH, 2022, 82 (12)
  • [4] CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
    van de Donk, Niels W. C. J.
    Usmani, Saad Z.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [5] Registering a CD38 antibody upfront for multiple myeloma
    Hofmeister, Craig C.
    Nooka, Ajay
    Kaufman, Jonathan L.
    Lonial, Sagar
    LANCET, 2019, 394 (10192): : 3 - 4
  • [6] CD38 Monoclonal Antibody Therapies for Multiple Myeloma
    Wong, Sandy W.
    Comenzo, Raymond L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 635 - 645
  • [7] Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
    C. Grandclément
    C. Estoppey
    E. Dheilly
    M. Panagopoulou
    T. Monney
    C. Dreyfus
    J. Loyau
    V. Labanca
    A. Drake
    S. De Angelis
    A. Rubod
    J. Frei
    L. N. Caro
    S. Blein
    E. Martini
    M. Chimen
    T. Matthes
    Z. Kaya
    C. M. Edwards
    J. R. Edwards
    E. Menoret
    C. Kervoelen
    C. Pellat-Deceunynck
    P. Moreau
    M. L. Mbow
    A. Srivastava
    M. R. Dyson
    E. A. Zhukovsky
    M. Perro
    S. Sammicheli
    Nature Communications, 15
  • [8] Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
    Grandclement, C.
    Estoppey, C.
    Dheilly, E.
    Panagopoulou, M.
    Monney, T.
    Dreyfus, C.
    Loyau, J.
    Labanca, V.
    Drake, A.
    De Angelis, S.
    Rubod, A.
    Frei, J.
    Caro, L. N.
    Blein, S.
    Martini, E.
    Chimen, M.
    Matthes, T.
    Kaya, Z.
    Edwards, C. M.
    Edwards, J. R.
    Menoret, E.
    Kervoelen, C.
    Pellat-Deceunynck, C.
    Moreau, P.
    Mbow, M. L.
    Srivastava, A.
    Dyson, M. R.
    Zhukovsky, E. A.
    Perro, M.
    Sammicheli, S.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [9] Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
    Kazandjian, Dickran
    Quach, Hang
    Sia, Hanlon
    Ho, Phoebe Joy
    Spencer, Andrew
    Schroeder, Mark A.
    Dhakal, Binod
    Cochrane, Tara
    Zonder, Jeffrey A.
    Yi, Nancy
    Duchesne, Dominique
    Shah, Tejas
    Garton, Andrew
    Menon, Vinu
    Gn, Sunitha
    Sammicheli, Stefano
    Zhukovsky, Eugene
    Konto, Cyril
    Pacaud, Lida
    Tan, Peter
    BLOOD, 2023, 142
  • [10] ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
    Grandclement, C.
    Estoppey, C.
    Dheilly, E.
    Panagopoulou, M.
    Martini, E.
    Labanca, V.
    De Angelis, S.
    Frei, J.
    Drake, A.
    Rubod, A.
    Gudi, G.
    Udupa, V.
    Olsen, J.
    Giovannini, R.
    Doucey, M.
    Feldman, E.
    Konto, C.
    Srivastava, A.
    Zhukovsky, E.
    Perro, M.
    Sammicheli, S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A6 - A7
12345